Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study To Evaluate The Long-Term Safety Of Subcutaneous MOA-728 For Treatment Of Opioid-Induced Constipation In Subjects With Nonmalignant Pain

Next Previous
Trial Profile

An Open-Label Study To Evaluate The Long-Term Safety Of Subcutaneous MOA-728 For Treatment Of Opioid-Induced Constipation In Subjects With Nonmalignant Pain

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methylnaltrexone bromide (Primary)
  • Indications Constipation
  • Focus Adverse reactions; Registrational
  • Sponsors Salix Pharmaceuticals

Most Recent Events

  • 03 Jun 2015 The EC approved RELISTOR (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, according to a Valeant Pharmaceuticals International and Progenics Pharmaceuticals media release.
  • 27 Apr 2015 The Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted a positive opinion recommending approval of methylnaltrexone bromide subcutaneous injection (RELISTOR) for the treatment of opioid-induced constipation in adults, according to a Valeant Pharmaceuticals International media release.
  • 03 Jun 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top